Physician profile
Elena Pollack
NPI 1366711350
$10,313.21
in general payments reported to CMS, 2019-2025
28 companies · $2,416 in 2025
The $2,416 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $531 · 2021: $1,053 · 2022: $1,476 · 2023: $1,886 · 2024: $2,179 · 2025: $2,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,138 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,137.59 |
| Education | $342.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,014.87 | 2019-2025 | |
| Leo Pharma INC. | $1,487.63 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $1,141.92 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $839.60 | 2021-2025 | |
| Pfizer INC. | $767.97 | 2019-2025 | |
| Incyte Corporation | $747.21 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $625.84 | 2019-2025 | Dupixent |
| Ucb, INC. | $404.92 | 2022-2025 | Briviact, Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $372.38 | 2019-2025 | Ilumya |
| Amgen INC. | $298.32 | 2020-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $225.57 | 2019-2025 | |
| Lilly USA, LLC | $219.10 | 2019-2025 | Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $201.39 | 2022-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $188.48 | 2019-2023 | |
| Galderma Laboratories, L.P. | $168.52 | 2019-2025 | Aklief, Nemluvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $103.96 | 2019-2024 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.68 | 2019-2023 | Targretin, Siliq |
| Arcutis Biotherapeutics, INC. | $78.15 | 2024-2025 | Zoryve |
| Botanix Sb INC | $64.07 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $51.82 | 2021-2023 | Pramosone, Naftin |
| Melinta Therapeutics, LLC | $48.55 | 2019 | |
| Journey Medical Corporation | $41.91 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $30.80 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.04 | 2025 | |
| Dermira, INC. | $22.84 | 2020 | |
| Organon LLC | $17.76 | 2025 | |
| Merck Sharp & Dohme LLC | $17.61 | 2019 | |
| Mission Pharmacal Company | $15.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.